Waterhouse D, et al. - Safety of 30- and 60-min infusions of nivolumab was compared in patients with previously treated advanced non-small cell lung cancer. Findings revealed that safety profile of nivolumab infused over 30 min was comparable to that of the 60-min infusion, including a low incidence of infusion-related reactions.